Ligand activation causes a phosphorylation-dependent change in platelet-derived growth factor receptor conformation.
The effect of ligand binding on platelet-derived growth factor (PDGF) receptor conformation was examined using peptide antibodies directed against specific receptor domains. Antiserum 83, which was directed to the receptor's carboxyl terminus (residues 934-951), preferentially immunoprecipitated the ligand-activated form of the PDGF receptor from 35S-labeled BALB/c 3T3 cells. By contrast, two antisera directed against other receptor sequences precipitated unactivated and activated receptors equally well. Denatured receptors were recognized equally by all antisera, even 83. Thus, ligand activation caused a change in PDGF receptor conformation that enhanced accessibility of the antibody to the carboxyl terminus. The activated receptor conformation was induced by three different forms of PDGF (AA and BB homodimers and AB heterodimers) and was reversed by suramin, a polyanionic compound that dissociates PDGF from the receptor. The inhibitory effect of suramin on receptor conformation was abolished by the phosphatase inhibitor, sodium orthovanadate, suggesting that receptor phosphorylation mediated the conformational change. In a cell-free assay, the change in receptor conformation was induced by PDGF only in the presence of ATP and was inhibited by adenyl-5'-yl imidodiphosphate, a nonhydrolyzable analog of ATP. The functional significance of receptor conformation was examined in Chinese hamster ovary fibroblasts transfected with wild-type or mutated forms of the PDGF receptor. When receptor tyrosine kinase activity was abolished by a mutation of the ATP binding site the receptor no longer underwent PDGF-induced conformational change and did not mediate PDGF-induced mitogenesis even though 125I-PDGF binding was normal. These findings show that ligand binding elicits a phosphorylation-dependent change in PDGF receptor conformation that may be important for receptor function.
Keating
M T
MT
University of California, Department of Medicine, San Francisco.
Escobedo
J A
JA
Williams
L T
LT
D000266:Adenylyl Imidodiphosphate / Q000494:pharmacology; D000818:Animals; D004261:DNA Replication / Q000187:drug effects; D051379:Mice; D008807:Mice, Inbred BALB C; D010766:Phosphorylation; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology; D011487:Protein Conformation; D011956:Receptors, Cell Surface / Q000032:analysis*; D017479:Receptors, Platelet-Derived Growth Factor; D013498:Suramin / Q000494:pharmacology; D014638:Vanadates / Q000494:pharmacology
D010982:Platelet-Derived Growth Factor; D011956:Receptors, Cell Surface; D000266:Adenylyl Imidodiphosphate; D014638:Vanadates; D013498:Suramin; D017479:Receptors, Platelet-Derived Growth Factor